Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.
about
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidenceLiraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.Novel insights in the metabolic syndrome-induced oxidative stress and inflammation-mediated atherosclerosis.GLP-1 response to sequential mixed meals: influence of insulin resistance.Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
P2860
Q26739999-D9A1E17C-B4F6-4CBE-A887-FC88884A6486Q33656442-C360D7C2-70B2-44CC-AA35-D49470C9EE6EQ35748827-ED106950-2FED-4B4E-8F0C-9A72177C843EQ37470522-CEC51929-1F11-4B18-A981-40BFCE54A811Q47223795-8671E16C-AF14-4FFB-A5AE-24F828210F0BQ47248842-9B11F956-DC45-4B39-BBC6-2D2B74EAF893Q47621594-AFFD0604-24BD-4CB9-B08E-3D2C62E1AC06Q48103910-57355FA5-E6FB-4D25-80D4-06B95989AAA7Q48340758-BC941E50-C043-4D5F-A78D-3EAFE3E898B5Q48488584-EA46A686-4EA1-43D3-AC71-96820592CAC5Q51278208-11C79A42-08C0-4EF5-89FA-17ECF47D1E50
P2860
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@ast
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@en
type
label
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@ast
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@en
prefLabel
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@ast
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@en
P2093
P2860
P356
P1433
P1476
Anti-atherosclerotic effects o ...... tes Mellitus: A meta-analysis.
@en
P2093
Hetang Jia
Liang Wang
Xiaoyan Song
Yuebo Jiang
P2860
P2888
P356
10.1038/SREP10202
P407
P577
2015-06-26T00:00:00Z
P5875
P6179
1039666689